Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis

Journal of Bone and Mineral Research

Volumn 24, Issue 8, 2009, Pages 1358-1368

  Recker, Robert R ^a   Marin, Fernando ^b   Ish Shalom, Sophia ^c   Möricke, Rüdiger ^d   Hawkins, Federico ^e   Kapetanos, Georgios ^f   De La Peña, Maria P ^g   Kekow, Jörn ^h   Farrerons, Jordi ⁱ   Sanz, Beatriz ^b   Oertel, Heide ^b   Stepan, Jan ^j  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c RAMBAM MEDICAL CENTER   (Israel)

^d Endocrinology Clinical Research Laboratory   (Germany)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^f ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^g Clínica Médica Monraz   (Mexico)

^h Speciality Hospital   (Germany)

ⁱ HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^j CHARLES UNIVERSITY   (Czech Republic)

more..

Author keywords

Bone biopsy; Bone marker; Osteoporosis; Strontium; Teriparatide

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; BIOCHEMICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; PARATHYROID HORMONE[1-34]; STRONTIUM RANELATE;

BONE BIOPSY; BONE MINERALIZATION; BONE REMODELING; BONE TURNOVER; CELL ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; HUMAN; MORPHOMETRICS; OSSIFICATION; OSTEOLYSIS; POROSITY; POSTMENOPAUSE OSTEOPOROSIS; STATISTICAL SIGNIFICANCE;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; FEMALE; HUMANS; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS; POSTMENOPAUSE; TERIPARATIDE; THIOPHENES;

EID: 68949100644     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.090315     Document Type: Conference Paper

References (43)

1. Delmas PD 2002 Treatment of postmenopausal osteoporosis. Lancet 359:2018-2026.
2. Riggs BL, Parfitt AM 2005 Perspective: Drugs used to treat osteoporosis: The critical need for a uniform nomenclature based on their action on bone remodeling. J Bone Miner Res 20:177-184.
3. Canalis E, Giustina A, Bilezikian JP 2007 Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 357:905-916.
4. Lindsay R, Zhou H, Cosman F, Nieves J, Dempster DW, Hodsman AB 2007 Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J Bone Miner Res 22:495-502. (Pubitemid 47457425)
5. Ma YL, Zeng Q, Donley DW, Ste-Marie LG, Gallagher JC, Dalsky GP, Marcus R, Eriksen EF 2006 Teriparatide increases bone formation in modeling and remodeling osteons and en- hances IGF-II immunoreactivity in postmenopausal women with osteoporosis. J Bone Miner Res 21:855-864. (Pubitemid 43787992)
6. Goltzman D 2008 Studies on the mechanisms of the skeletal anabolic action of endogenous and exogenous parathyroid hormone. Arch Biochem Biophys 473:218-224.
7. Canalis E, Hott M, Deloffre P, Tsouderos Y, Marie PJ 1996 The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone 18:517-523. (Pubitemid 26257871)
8. Takahashi N, Sasaki T, Tsuoderos Y, Suda TS 2003 12911-2 inhibits osteoclastic bone resorption in vitro. J Bone Miner Res 18:1082-1087. (Pubitemid 37294946)
9. Marie PJ, Ammann P, Boivin G, Rey C 2001 Mechanisms of action and therapeutic potential of strontium in bone. Calcif Tissue Int 69:121-129. (Pubitemid 32912229)
10. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY 2004 The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459-468. (Pubitemid 38133766)
11. Meunier PJ, Slosman D, Delmas P, Sebert JL, Brandi ML, Albanese C, Lorenc R, Pors-Nielsen S, De Vernejoul MC, Roces A, Reginster JY 2002 Strontium ranelate: Dose-dependent effects in established postmenopausal vertebral osteoporosis: A 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 87:2060-2066. (Pubitemid 34521489)
12. Arlot ME, Jiang Y, Genant HK, Zhao J, Burt-Pichat B, Roux J-P, Delmas PD, Meunier PJ 2008 Histomorphometric and μCT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate. J Bone Miner Res 23:215-222. (Pubitemid 351160035)
13. Goldner J 1938 A modification of the Masson trichrome technique for routine laboratory purposes. Am J Pathol 14:237-243.
14. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595-610.
15. Hodsman AB, Kisiel M, Adachi JD, Fraher LJ, Warson PH 2000 Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1-34) therapy in women with severe osteoporosis. Bone 27:311-318. (Pubitemid 30458828)
16. Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF 2003 Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 18:1932-1941. (Pubitemid 37377441)
17. Arlot M, Meunier PJ, Boivin G, Haddock L, Tamayo J, CorreaRotter R, Jasqui S, Donley DW, Dalsky GP, Martin JS, Eriksen EF 2005 Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res 20:1244-1253. (Pubitemid 40863814)
18. McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, Donley DW, Dalsky GP, Eriksen EF 2005 Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 165:1762-1768. (Pubitemid 41138965)
19. - zynski WP, Orwoll E, Yuen CK 2005 Parathyroid hormone and teriparatide for the treatment of osteoporosis: A review of the evidence and suggested guidelines for its use. Endocr Rev 26:688-703. (Pubitemid 41127277)
20. Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman JM, Clancy AD, Gaich GA 2003 The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9-17. (Pubitemid 36008334)
21. Boonen S, Marin F, Obermayer-Pietsch B, Simões ME, Barker C, Glass EV, Lyritis G, Oertel H, Nickelsen T, McCloskey EV, for the Eurofors Investigators 2008 Effects of prior antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 93:852-860.
22. Amman P, Shen V, Robin B, Mauras Y, Bonjour JP, Rizzoli R 2004 Strontium ranelate improves bone resistance by increasing bone mass and improving architecture in intact female rats. J Bone Miner Res 19:2012-2020. (Pubitemid 41103416)
23. Fuchs RK, Allen MR, Condon KW, Reinwald S, Miller LM, McClenathan D, Keck B, Philipps RJ, Burr DB 2008 Strontium ranelate does not stimulate bone formation in ovariectomized rats. Osteoporos Int 19:1331-1341.
24. Jerome CT, Burr DB, Van Bibber T, Hock JM, Brommage R 2001 Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone 28:150-159.
25. Sato M, Westmore M, Ma YL, Schmidt A, Zeng QQ, Glass EV, Vahle J, Brommage R, Jerome CP, Turner CH 2004 Teriparatide [PTH(1-34)] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity. J Bone Miner Res 19:623-629. (Pubitemid 41071223)
26. Recker RR, Kimmel DB, Parfitt AM, Davies M, Keshawarz N, Hinders S 1988 Static and tetracycline-based bone histomorphometric data from 34 normal postmenopausal females. J Bone Miner Res 3:133-144. (Pubitemid 18209860)
27. Keshawarz NM, Recker RR 1984 Expansion of the medullary cavity at the expense of cortex in postmenopausal osteoporosis. Metab Bone Dis Relat Res 5:223-228.
28. Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetic K, Muller R, Bilezikian J, Lindsay R 2001 Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study. J Bone Miner Res 16:1846-1853. (Pubitemid 32911491)
29. Lindsay R, Cosman F, Zhou H, Bostrom MP, Shen VW, Cruz JD, Nieves JW, Dempster DW 2006 A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: Early actions of teriparatide. J Bone Miner Res 21:366-373. (Pubitemid 43306557)
30. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier P 1997 Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100:1475-1480. (Pubitemid 27425772)
31. Borah B, Dufresne TE, Chmielewski PA, Johnson TD, Chines A, Manhart MD 2004 Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone 34:736-746. (Pubitemid 38393811)
32. Recker RR, Delmas PD, Halse J, Reid IR, Boonen S, Garcia-Hernandez PA, Suporonik J, Lewiecki EM, Ochoa L, Miller P, Hu H, Mesenbrink P, Hartl F, Gasser J, Eriksen EF 2007 The effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res 23:6-16.
33. Brixen K, Krogsgaard K, Christgau S, Weis M, Eastell R 2008 Effect of three doses of strontium malonate (NBSlOl) on markers of bone turnover and bone mineral density: The STRONG Study. Calcif Tissue Int 82(Suppl 1):S217.
34. Eastell R, Krege JH, Chen P, Glass EV, Reginster J-Y 2006 Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin 22:61-66. (Pubitemid 43106908)
35. Durham BH, Joshi AA, Ahmad AM, Vora JP, Fraser WD 2007 The effects of strontium ranelate on biochemical bone markers in elderly women and men with reduced bone mineral density. J Bone Miner Res 22:S1;S336.
36. Reginster JY, Deroisy R, Dougados M, Jupsin I, Colette J, Roux C 2002 Prevention of early postmenopausal bone loss by strontium ranelate: The randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial. Osteoporos Int 13:925-931. (Pubitemid 36050269)
37. Calvo MA, Eyre DR, Gunberg CM 1996 Molecular basis and clinical applications of biological markers of bone turnover. Endocr Rev 17:333-368. (Pubitemid 26277979)
38. Choudhary S, Halbout P, Alander C, Raisz L, Pilbeam C 2007 Strontium ranelate promotes osteoblastic differentiation and mineralization of murine bone marrow stromal cells: Involvement of prostaglandins. J Bone Miner Res 22:1002-1010. (Pubitemid 351339722)
39. Neer RM, Arnaud C, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Mellstrom D, IshShalom S, Oefjord ES, Marcinowska-Suchowierska E, Salmi J, Gaspar L, Mulder H, Halse J, Sawicki AZ, Genant H, Wang O, Mitlak BH 2001 Recombinant human PTH [rhPTH(1-34)] reduces the risk of spine and non-spine fractures in postmenopausal osteoporosis. N Engl J Med 344:1434-1441.
40. Hodsman AB, Steer BM 1993 Early histomorphometric changes in response to parathyroid hormone therapy in osteoporosis: Evidence for de novo bone formation on quiescent cancellous surfaces. Bone 14:523-527.
41. Hauge EM, Mosekilde Le, Meisen F, Frydenburg M 2001 How many patients are needed? Variation and design considerations in bone histomorphometry. Bone 28:556-562.
42. Blake GM, Fogelman I 2005 Long-term effect of strontium ranelate treatment on BMD. J Bone Miner Res 20:1901-1904. (Pubitemid 41532774)
43. Graeff C, Timm W, Nickelsen TN, Farrerons J, Marin F, Barker C Glüer C-C, for the EUROFORS High Resolution Quantitative Computed Tomography Substudy Group 2007 Monitoring teriparatide-associated changes in vertebral microstructure by high-resolution CT in vivo: Results from the EUROFORS study. J Bone Miner Res 22:1426-1433.